These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 37561343)

  • 1. The 2022 PSOGI International Consensus on HIPEC Regimens for Peritoneal Malignancies: Epithelial Ovarian Cancer.
    Bhatt A; Glehen O; Zivanovic O; Brennan D; Nadeau C; Van Driel W; Bakrin N
    Ann Surg Oncol; 2023 Dec; 30(13):8115-8137. PubMed ID: 37561343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2022 PSOGI Consensus on HIPEC Regimens for Peritoneal Malignancies: Diffuse Malignant Peritoneal Mesothelioma.
    Kepenekian V; Sgarbura O; Marchal F; Villeneuve L; Kusamura S; Deraco M
    Ann Surg Oncol; 2023 Nov; 30(12):7803-7813. PubMed ID: 37481492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2022 Peritoneal Surface Oncology Group International Consensus on HIPEC Regimens for Peritoneal Malignancies: Colorectal Cancer.
    Hübner M; van Der Speeten K; Govaerts K; de Hingh I; Villeneuve L; Kusamura S; Glehen O
    Ann Surg Oncol; 2024 Jan; 31(1):567-576. PubMed ID: 37940803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The 2022 PSOGI International Consensus on HIPEC Regimens for Peritoneal Malignancies: Pseudomyxoma Peritonei.
    Kusamura S; Delhorme JB; Taibi A; Villeneuve L; Deraco M; Dico RL; Glehen O; Moran B
    Ann Surg Oncol; 2024 Sep; 31(9):6262-6273. PubMed ID: 39008204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The 2022 PSOGI International Consensus on HIPEC Regimens for Peritoneal Malignancies: HIPEC Technologies.
    Van der Speeten K; Kusamura S; Villeneuve L; Piso P; Verwaal VJ; González-Moreno S; Glehen O
    Ann Surg Oncol; 2024 Oct; 31(10):7090-7110. PubMed ID: 39037523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The 2022 PSOGI International Consensus on HIPEC Regimens for Peritoneal Malignancies: Methodology.
    Kusamura S; Bhatt A; Hubner M; Villeneuve L; Deraco M; Bakrin N; Van Der Speeten K; Glehen O
    Ann Surg Oncol; 2023 Apr; 30(4):2508-2519. PubMed ID: 36595113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) with primary or secondary cytoreductive surgery in the treatment of advanced epithelial ovarian cancer.
    Manzanedo I; Pereira F; Pérez-Viejo E; Serrano Á; Hernández-García M; Martínez-Torres B; Rihuete-Caro C; Calzas J; Cueto M
    Minerva Ginecol; 2017 Apr; 69(2):119-127. PubMed ID: 27415829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIPEC ROC I: a phase I study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer.
    Zivanovic O; Abramian A; Kullmann M; Fuhrmann C; Coch C; Hoeller T; Ruehs H; Keyver-Paik MD; Rudlowski C; Weber S; Kiefer N; Poelcher ML; Thiesler T; Rostamzadeh B; Mallmann M; Schaefer N; Permantier M; Latten S; Kalff J; Thomale J; Jaehde U; Kuhn WC
    Int J Cancer; 2015 Feb; 136(3):699-708. PubMed ID: 24895230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mininvasive Cytoreduction Surgery plus HIPEC for Epithelial Ovarian Cancer: A Systematic Review.
    Ronsini C; Pasanisi F; Greco P; Cobellis L; De Franciscis P; Cianci S
    Medicina (Kaunas); 2023 Feb; 59(3):. PubMed ID: 36984422
    [No Abstract]   [Full Text] [Related]  

  • 10. HIPEC plus EPIC paclitaxel for maximal perioperative treatments of advanced epithelial ovarian cancer. Long-term results of a pilot study.
    Sugarbaker PH; Stuart OA
    Surg Oncol; 2020 Dec; 35():441-446. PubMed ID: 33039850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Indications for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: a systematic review.
    Auer RC; Sivajohanathan D; Biagi J; Conner J; Kennedy E; May T
    Eur J Cancer; 2020 Mar; 127():76-95. PubMed ID: 31986452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytoreductive Surgery (CRS) Combined With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Platinum-Sensitive Recurrence Epithelial Ovarian Cancer With HRR Mutation: A Phase III Randomized Clinical Trial.
    Qi Y; Zhang Y; Shi Y; Yao S; Dai M; Cai H
    Technol Cancer Res Treat; 2022; 21():15330338221104565. PubMed ID: 35929135
    [No Abstract]   [Full Text] [Related]  

  • 13. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer.
    Gelissen JH; Adjei NN; McNamara B; Mutlu L; Harold JA; Clark M; Altwerger G; Dottino PR; Huang GS; Santin AD; Azodi M; Ratner E; Schwartz PE; Andikyan V
    Ann Surg Oncol; 2023 Sep; 30(9):5597-5609. PubMed ID: 37358686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Sodium Thiosulfate on Prevention of Nephrotoxicities in HIPEC: An Ancillary Evaluation of Cisplatin-Induced Toxicities in Ovarian Cancer.
    Senguttuvan RN; Santiago NL; Han ES; Lee B; Lee S; Lin WC; Kebria M; Hakim A; Lin JF; Wakabayashi MT; Ruel N; Tinsley R; Eng M; Stewart DB; Wang EW; Paz BI; Wu X; Cho H; Liang WS; Rodriguez-Rodriguez L; Cristea MC; Raoof M; Dellinger TH
    Ann Surg Oncol; 2023 Dec; 30(13):8144-8155. PubMed ID: 37710139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes for Elderly Ovarian Cancer Patients Treated with Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC).
    Zambrano-Vera K; Sardi A; Lopez-Ramirez F; Sittig M; Munoz-Zuluaga C; Nieroda C; Gushchin V; Diaz-Montes T
    Ann Surg Oncol; 2021 Aug; 28(8):4655-4666. PubMed ID: 33393042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperthermic Intraperitoneal Chemotherapy in the Management of Primary Epithelial Ovarian Cancer: A Debated Issue for Gynecologic Oncologists.
    Gadducci A; Cosio S; Lippolis PV
    Anticancer Res; 2022 Oct; 42(10):4659-4665. PubMed ID: 36191972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival After Hyperthermic Intraperitoneal Chemotherapy and Primary or Interval Cytoreductive Surgery in Ovarian Cancer: A Randomized Clinical Trial.
    Lim MC; Chang SJ; Park B; Yoo HJ; Yoo CW; Nam BH; Park SY;
    JAMA Surg; 2022 May; 157(5):374-383. PubMed ID: 35262624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decision-Making Analysis for Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer: A Survey by the Executive Committee of the Peritoneal Surface Oncology Group International (PSOGI).
    Steffen T; Häller L; Bijelic L; Glatzer M; Glehen O; Goéré D; de Hingh I; Li Y; Moran BJ; Morris DL; Piso P; Quadros CA; Rau B; Sugarbaker P; Yonemura Y; Putora PM
    Oncology; 2021; 99(1):41-48. PubMed ID: 32920557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperthermic intraperitoneal chemotherapy for epithelial ovarian cancer: A meta-analysis.
    Kim SI; Kim JH; Lee S; Cho H; van Driel WJ; Sonke GS; Bristow RE; Park SY; Fotopoulou C; Lim MC
    Gynecol Oncol; 2022 Dec; 167(3):547-556. PubMed ID: 36273925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patterns of recurrence in women with advanced and recurrent epithelial ovarian cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Chambers LM; Yao M; Morton M; Gruner M; Chichura A; Horowitz M; Costales AB; Rose PG; Michener CM; Debernardo R
    Gynecol Oncol; 2021 May; 161(2):389-395. PubMed ID: 33551202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.